Diversified Trust Co Buys 6,736 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Diversified Trust Co increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 29.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,810 shares of the medical research company's stock after purchasing an additional 6,736 shares during the quarter. Diversified Trust Co's holdings in Edwards Lifesciences were worth $2,161,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC boosted its stake in Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after buying an additional 126,194 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $610,895,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $74.40, for a total transaction of $837,000.00. Following the transaction, the chief financial officer now owns 41,098 shares in the company, valued at approximately $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the transaction, the chief executive officer now owns 58,284 shares in the company, valued at approximately $4,366,054.44. This represents a 9.31% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 40,648 shares of company stock valued at $2,998,866. Insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EW. Robert W. Baird increased their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Truist Financial dropped their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Finally, Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Trading Up 1.2%

Shares of EW stock traded up $0.92 on Friday, reaching $78.07. 6,205,587 shares of the company's stock were exchanged, compared to its average volume of 5,242,644. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $45.80 billion, a PE ratio of 11.15, a P/E/G ratio of 3.94 and a beta of 1.12. The company's fifty day simple moving average is $75.62 and its 200 day simple moving average is $73.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the company earned $0.66 EPS. Edwards Lifesciences's quarterly revenue was up 6.2% compared to the same quarter last year. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.